William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

Benzinga Newsdesk www.benzinga.com Positive 87.3%

Neg 0% Neu 0% Pos 87.3%

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.